New Dual-Targeting drug shows promise in early cancer trial
NCT ID NCT07067567
First seen Nov 01, 2025 · Last updated Apr 27, 2026 · Updated 29 times
Summary
This early-phase study tests a new drug called AK146D1 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two targets on cancer cells to deliver a toxic payload directly. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors. About 200 adults aged 18 to 75 with good organ function and measurable tumors may join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SunYat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.